IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re: Apple Tree Life Sciences, Inc., *et al.*,[1] Debtors.	Chapter 11 Case No. 25-12177 (LSS) (Jointly Administered) **Re: D.I. 1243**

CERTIFICATE OF NO OBJECTION REGARDING FIRST MONTHLY FEE STATEMENT OF DLA PIPER LLP (US) FOR THE PERIOD FROM JULY 7, 2026, THROUGH AND INCLUDING AUGUST 31, 2026

I, R. Craig Martin, a partner with DLA Piper LLP (US) ("DLA Piper"), as counsel to ATP Life Science Ventures, L.P. (the "Fund Debtor"), in the above-captioned chapter 11 cases, certify as follows:

1. On October 21, 2026, DLA Piper, counsel for the Fund Debtor, filed the *First Monthly Fee Statement of DLA Piper LLP (US) for the Period from July 7, 2026, Through and Including August 31, 2026* [D.I. 1243] (the "Fee Statement") with the United States Bankruptcy Court for the District of Delaware (the "Court").

2. The deadline for objections or responses to the Fee Statement was November 4, 2026, at 4:00 p.m. (ET).

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The service address for ATP Life Science Ventures, L.P. is c/o Alvarez & Marsal Cayman Islands Limited, Attn: Kim Dennison, 2nd Floor, Flagship Building, 142 Seafarers Way, P.O. Box 2507, George Town, Grand Cayman, Cayman Islands, KY1-1104. The service address for each of the remaining Debtors is 230 Park Avenue, Suite 2800, New York, NY 10169.

25121772611050000000000005

3. The objection deadline has passed and no objections or responses to the Fee Statement were filed.

4. Pursuant to the *Order (I) Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals and (II) Granting Related Relief* [D.I. 181], the Fund Debtor is now authorized to pay DLA Piper $820,053.86, which is 80% of the fees and 100% of the expenses requested in the Fee Statement, without further Court order.

[*Remainder of page left intentionally blank*]

Dated: November 5, 2026
Wilmington, Delaware

Respectfully submitted,

DLA PIPER LLP (US)

/s/ R. Craig Martin

R. Craig Martin (DE No. 5032)
DLA Piper LLP (US)
1201 North Market Street, Suite 2100
Wilmington, Delaware 19801
Telephone: (302) 468-5700
Facsimile: (302) 394-2341
Email: craig.martin@us.dlapiper.com

-and-

Gregory M. Juell (NY No. 5420120)
DLA Piper LLP (US)
1251 Avenue of the Americas
New York, New York 10020
Telephone: (212) 335-4000
Facsimile: (212) 335-4501
Email: gregory.juell@us.dlapiper.com

-and-

Shant K. A. Eulmessekian (NY No. 6094668)
DLA Piper LLP (US)
2000 Avenue of the Stars, Suite 400 North Tower
Los Angeles, California 90067
Telephone: (310) 595-3000
Facsimile: (310) 595-3300
Email: shant.eulmessekian@us.dlapiper.com

Counsel to the Fund Debtor